Bibliography
- Scannell WS, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Rev Drug Discov 2012;11:191-200
- Cha M, Rifai B, Sarraf P. Pharmaceutical forecasting: throwing darts? Nature Rev Drug Discov 2013;12:737-8
- Priority Medicines for Europe and the World Update Report. 2013. Available from: http://www.who.int/medicines/areas/priority_medicines/en/ [Last accessed 21 January 2015]
- Lincker H, Ziogas C, Carr M, et al. Regulatory watch: where do new medicines originate frm in EU? Nat Rev Drug Discov 2014;13:92-3
- Melchiorri D, Pani L, Gasparini P, et al. Regulatory evaluation of Glybera in Europe - two committees, one mission. Nat Rev Drug Discov 2013;12(9):719-23
- Eichler HG, Oye K, Baird LG, et al. Adaptive licensing taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012;91:426-37
- Regulation (EU) No. 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Official journal of the european union. 2014.57. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L:2014:158:FULL&from=DE [Last accessed 21 January 2015]
- Commission Implementing Regulation (EU) No. 520/2012. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF [Last accessed 21 January 2015]
- European Medicines Agency. European Medicines Agency policy on publication of clinical data for medicinal products for human use. Policy/0070. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/10/WC500174796.pdf [Last accessed 21 January 2015]
- Bonini S, Eichler HG, Wathion N, et al. Publication of clinical trial data – the european medicines agency driving transparency. New Engl J Med 2014;371:2452-5